MARKET

SLDB

SLDB

Solid Bioscience
NASDAQ
2.590
-0.780
-23.15%
After Hours: 2.650 +0.06 +2.32% 19:55 05/07 EDT
OPEN
3.450
PREV CLOSE
3.370
HIGH
3.495
LOW
2.530
VOLUME
2.86M
TURNOVER
--
52 WEEK HIGH
10.99
52 WEEK LOW
2.450
MARKET CAP
200.71M
P/E (TTM)
-0.8478
1D
5D
1M
3M
1Y
5Y
1D
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
Benzinga · 10h ago
BUZZ-Gene therapy and vaccine makers fall after FDA names Vinay Prasad as top vaccine official
Reuters · 1d ago
GENE THERAPY MAKERS FALL AFTER US FDA NAMES ONCOLOGIST VINAY PRASAD AS TOP VACCINE OFFICIAL
Reuters · 1d ago
U.S.-LISTED SHARES OF CRISPR THERAPEUTICS FALL 10.3%, SAREPTA THERAPEUTICS FALL 20.2%
Reuters · 1d ago
Weekly Report: what happened at SLDB last week (0428-0502)?
Weekly Report · 2d ago
SOLID BIOSCIENCES REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 6d ago
Weekly Report: what happened at SLDB last week (0421-0425)?
Weekly Report · 04/28 09:10
Piper Sandler Remains a Buy on Solid Biosciences (SLDB)
TipRanks · 04/21 10:57
More
About SLDB
More
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The Company also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. It also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Recently
Symbol
Price
%Change

Webull offers Solid Biosciences Inc stock information, including NASDAQ: SLDB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLDB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLDB stock methods without spending real money on the virtual paper trading platform.